Vertex Pharmaceuticals (VRTX) Q3 2018 Results - Earnings Call Transcript

10/25/18

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Q3 2018 Earnings Call October 24, 2018 4:30 PM ET

Executives

Michael Partridge - Vertex Pharmaceuticals, Inc.

Jeffrey M. Leiden - Vertex Pharmaceuticals, Inc.

Ian F. Smith - Vertex Pharmaceuticals, Inc.

Reshma Kewalramani - Vertex Pharmaceuticals, Inc.

Stuart A. Arbuckle - Vertex Pharmaceuticals, Inc.

Analysts

Phil Nadeau - Cowen & Co. LLC

Geoff Meacham - Barclays Capital, Inc.

Michael J. Yee - Jefferies LLC

Robyn Karnauskas - Citigroup Global Markets, Inc.

Geoffrey C. Porges - Leerink Partners LLC

Terence Flynn - Goldman Sachs & Co. LLC

Ying Huang - Bank of America Merrill Lynch

Brian Abrahams - RBC Capital Markets LLC

Cory W. Kasimov - JPMorgan Securities LLC

Michael Partridge - Vertex Pharmaceuticals, Inc.

Welcome to the Vertex Third Quarter 2018 Conference Call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Tonight, we will review our financial results, our continued progress to develop new medicines for all people with cystic fibrosis and recent advances in our research and development pipeline.

Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Operating Officer, will provide prepared remarks this evening. Stuart Arbuckle, Chief Commercial Officer; and Dr. Reshma Kewalramani, Chief Medical Officer, will join us for Q&A. We recommend that you access the webcast slides on our website as you listen to this call. This conference call is being recorded. A replay will be available on our website.

We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and our filings with the Securities and Exchange Commission. These statements including, without limitation, those regarding Vertex's marketed CF medicines, the ongoing development and potential commercialization of our triple-combination regimen for cystic fibrosis, Vertex's other programs and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.

I will now turn the call over to Dr. Jeff Leiden.

READ FULL ARTICLE HERE